KSA Point-of-Care Molecular Diagnostics Market

KSA Point-of-Care Molecular Diagnostics Market Overview

• KSA Point-of-Care (POC) Molecular Diagnostics Market has experienced notable growth, this is reflected in the global Point-of-Care Diagnostics market valued at USD 2 billion in 2023. This growth is primarily driven by the increasing prevalence of infectious diseases, rising demand for rapid diagnostic techniques, and advancements in molecular diagnostic technologies.
• Key players in the KSA POC Molecular Diagnostics Market include Abbott Laboratories, Roche Diagnostics, Cepheid, BioMérieux and Thermo Fisher Scientific. These companies are leading the market with their innovative products and extensive distribution networks.
• In 2023, Roche Diagnostics launched its cobas® Liat® system in Saudi Arabia, a highly efficient and rapid point-of-care molecular testing device. The cobas® Liat® system fully automates the PCR process, allowing the rapid and accurate analysis of single samples.

KSA Point-of-Care Molecular Diagnostics Current Market Analysis

• Continuous innovations in molecular diagnostic technologies, such as next-generation sequencing (NGS) and CRISPR-based diagnostics, are significantly enhancing the accuracy, speed, and range of diagnostics available at the point of care.
• The impact of growth drivers is substantial, leading to quicker diagnosis, timely treatment, and better patient outcomes. Moreover, the integration of advanced diagnostics at the point of care reduces the burden on centralized laboratories and enhances the overall efficiency of healthcare services.
• The Central Region, including Riyadh, is dominating the market in particular. This dominance is due to the concentration of advanced healthcare facilities, higher investment in healthcare infrastructure, and the presence of major diagnostic companies.

KSA Point-of-Care Molecular Diagnostics Market Segmentation

By Application: By application, the KSA point-of-care molecular diagnostics market is segmented into infectious disease testing, oncology testing, genetic testing & others. In 2023, Infectious disease testing dominates due to the high prevalence of infectious diseases and the critical need for rapid diagnosis to prevent outbreaks.

By Technology: By technology, the market is segmented into PCR-based testing, isothermal amplification and next generation sequencing. In 2023, PCR-based testing dominates because of its high accuracy, reliability, and wide application in detecting various pathogens and genetic anomalies.

By End-Users: The market is segmented into hospitals, diagnostic centres, research laboratories and others. In 2023, Hospitals is dominate as they are the primary centers for diagnosing and treating serious health conditions, ensuring a steady demand for advanced diagnostics.

KSA Point-of-Care Molecular Diagnostics Market Competitive Landscape

• Roche Diagnostics: In March 2024, Roche acquired the point-of-care (POC) testing technology from LumiraDX, a London-based company, for $295 million. This acquisition is expected to close in mid-2024 and will enable Roche to transform testing at the point of care.
• Thermo Fisher Scientific: In February 2023, Thermo Fisher Scientific announced the launch of its Applied Biosystems TaqPath PCR kits for infectious diseases like multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27).
• Cepheid (Danaher Corp): In 2022, Cepheid launched the Xpert® MTB/RIF Ultra test in Saudi Arabia, significantly enhancing the diagnosis and management of tuberculosis (TB). This test offers improved sensitivity and faster results, enabling healthcare providers to quickly and accurately diagnose TB and detect rifampicin resistance.

KSA Point-of-Care Molecular Diagnostics Industry Analysis

KSA Point-of-Care Molecular Diagnostics Growth Drivers

• Saudi Vision 2030 Initiative: In 2023, the government allocated USD 50.4 billion towards healthcare infrastructure development, enhancing the adoption of advanced diagnostic technologies, including POC molecular diagnostics. The initiative aims to increase private sector contribution, thereby promoting investments in healthcare innovations and technologies.
• Healthcare Infrastructure Development: The Saudi government has been aggressively investing in the expansion and modernization of healthcare facilities. In 2023, the number of hospitals was 497, with an emphasis on incorporating advanced diagnostic equipment. This expansion is supported by the government's budget allocation of USD 50.4 billion for healthcare and social development in 2023. Such investments directly enhance the capacity and capabilities of healthcare providers to implement POC molecular diagnostics.
• Increased Prevalence of Chronic and Infectious Diseases: The rise in chronic and infectious diseases within Saudi Arabia is a significant driver for the POC molecular diagnostics market. According to the World Health Organization (WHO), non-communicable diseases like cancer kill 41 million people, out of which 80% of premature deaths come from low- & middle-income countries like Saudi Arabia.

KSA Point-of-Care Molecular Diagnostics Market Challenges

• Stringent Approval Processes: The Saudi Food and Drug Authority (SFDA) has stringent regulatory requirements for the approval of new diagnostic tests. The approval process for POC molecular diagnostics can take up to 18 months, delaying market entry and innovation. This regulatory bottleneck affects the speed at which new and advanced diagnostic technologies can be adopted, potentially hindering market growth.
• Cost Constraints: The high cost of POC molecular diagnostic devices and tests can be a significant barrier, particularly for smaller healthcare facilities and clinics. The average cost of a PCR-based POC diagnostic test ranges from USD 50 to USD 100, which may not be affordable for all segments of the population.
• Regulatory and Compliance Issues: Regulatory and compliance issues also pose challenges to the market. The stringent regulatory framework for the approval of diagnostic tools can delay the introduction of new technologies. These regulatory hurdles can slow down the market's growth by delaying the availability of innovative diagnostic solutions.

KSA Point-of-Care Molecular Diagnostics Recent Developments

• Siemens Healthineers’ Launches Atellica IM Analyzer: In 2023, Siemens Healthineers expanded its molecular point-of-care testing capabilities in Saudi Arabia by introducing the Atellica IM Analyzer. This analyzer allows for rapid and accurate testing of various infectious diseases, including COVID-19 and hepatitis. It integrates multiple diagnostic technologies, providing comprehensive diagnostic capabilities in a single platform.
• BD Diagnostics Launch of BD Max System: In 2023, BD launched the BD MAXâ„¢ system in Saudi Arabia, an automated molecular diagnostic platform designed for a variety of infectious disease assays. The BD MAXâ„¢ system offers flexibility and high throughput, meeting the needs of modern laboratories.
• BioFire Launched by BioMerieux: In 2022, BioMérieux launched its BioFire® FilmArray® panels in Saudi Arabia, offering comprehensive syndromic testing for respiratory, gastrointestinal, and bloodstream infections. These panels provide rapid, accurate results, enabling healthcare professionals to make timely and informed treatment decisions, significantly improving patient outcomes.

KSA Point-of-Care Molecular Diagnostics Future Market Outlook

The KSA POC Molecular Diagnostics Market is expected to continue growing from 2023 to 2028. Key drivers include technological advancements, the rising prevalence of chronic and infectious diseases, and ongoing government initiatives to improve healthcare infrastructure.

Future Market Trends:

• Increasing Adoption of Personalized Medicine: The shift towards personalized medicine is driving the demand for POC molecular diagnostics that offer rapid and precise genetic profiling. This trend is supported by the global push towards precision healthcare, aiming to improve patient outcomes through customized treatment plans.
• Advancements in Genetic Testing: Technological advancements in genetic testing, such as CRISPR and next-generation sequencing (NGS), will become more accessible at the point of care. These advancements enhance the capabilities of POC molecular diagnostics, making them more integral to modern healthcare.
• Integration with Digital Health Platforms: The integration of POC molecular diagnostics with digital health platforms is enhancing data management and patient monitoring. This trend supports the efficient use of diagnostic data, improving overall healthcare delivery and patient outcomes.